Horn & Co. has been recognized by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences. Yuval Horn was noted as a Tier I practitioner. Legal 500 notes: “the firm has been active at the ‘top level’ in the healthcare sector for over 20 years”
April 23, 2017
Yuval Horn, Roy Ribon and Yasmin Zohar of Horn & Co. acted as Israeli counsel to Therapix Biosciences Ltd. (NASDAQ: TRPX) (TASE: THXBY), in its listing on Nasdaq and offering of $12 million
March 23, 2017
Horn & Co. once again recognized as one of the elite law firms in Israel by Dun & Bradstreet, in its 2017 ranking by fields of expertise
March 17, 2017
Adv. Yuval Horn participated in the 3rd Silicon Beach Conference All Along the Spectrum – From Start-Up to IPO/Exit and Beyond
February 1, 2017
Yuval Horn was noted as one of leading practitioners in Israel in the field of Information Technology by the 2017 edition of Who’s Who Legal: Telecommunications Media & Technology
January 11, 2017
Adv. Paz Abercohen joined the firm as a partner
January 10, 2017
Yuval Horn and Ohad Mamann of Horn & Co. represented the investors in ArtsAvit’s financing round, led by Pontifax, Arkin Holdings and Merck Ventures
January 5, 2017
Vascular Biogenics Ltd. (NASDAQ:VBLT) Announces $24 Million Registered Direct Offering
December 18, 2016
Yuval Horn and Paz Abercohen of Horn & Co. acted as Israeli counsel to Protalix BioTherapeutics, Inc. (NYSE: PLX) in a $54.1 Million private notes exchange agreement, and a $22.5 Million private placement of the company’s Secured Convertible Notes
December 8, 2016
IBA 2nd M&A conference in the technology sector crowned with success
October 30, 2016
